ReviewDiabetology international2021
Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus.
Shubham Atal et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
ReviewDiabetology international2021
Shubham Atal et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.